Ulrich Schraermeyer and the Tübingen Bevacizumab Study
Group (Tübingen)
Development anti-VEGF antibody: preclinical, clinical and postclinical studies

Lutz Hesse (Heilbronn)
Intravitreal TPA: a precursor of anti-VEGF therapy?

Jerry Sebag (Huntington Beach)
Pharmacologic Vitreolysis – the first decade

Mike T. Trese (Royal Oak)
Microplasmin induced vitreous detachment and the role of oxygenation

Frank H. J. Koch (Frankfurt/M.)
Combination treatment including a limited vitrectomy

Andreas Wedrich (Graz)
Is there an evidence for an adjunctive intravitreal pharmacotherapy in vitreo-retinal surgery?

Michael J. Koss (Frankfurt/M.)
Limited Vitrectomy: liquifaction and posterior vitreous detachment? Experimental results and clinical observations.

Ralf Blank (Rüsselsheim)
The use of anti -VEGF Inhibitors in wet AMD: balancing the risks

Stephan Michels (Zürich)
OCT guided anti-VEGF therapy for neovascular AMD

Salvatore Grisanti (Lübeck)
Anti-VEGF: developments, comparison, new drugs